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Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by
the production of multiple autoantibodies. Antibodies against Ficolin-3 were previously iden-
tified in the sera of some SLE patients, but their prevalence and significance have not been
yet investigated. The aims of this study were to determine the prevalence of anti-ficolin-3
antibodies among SLE patients and to investigate their potential as diagnostic and/or prog-
nostic biomarkers in SLE. In this retrospective study, sera fromSLE patients (n = 165) were
selected from a preexisting declared biological collection. Samples from healthy controls
(n = 48) were matched with SLE sera. Disease activity was determinedaccording to the
SLEDAI score. Anti-ficolin-3, anti-dsDNA and anti-C1q antibodies levels were measured in
sera by ELISA. First, a highly significant difference was found in the anti-ficolin-3 levels
between SLE patients and healthy subjects. Anti-ficolin-3 antibodies were detected as posi-
tive in 56 of 165 (34%) SLE patients. The titer of anti-ficolin-3 antibodies was correlatedwith
the SLEDAI score (r = 0.38, p<0.0001). The presence of anti-ficolin-3 antibodies was asso-
ciated with anti-C1q and anti-dsDNA antibodies. Regarding associations with clinical mani-
festations, the presence of active lupus nephritis was significantly associated with the
presence of anti-ficolin-3 antibodies (p0.001). This association with renal involvement
was higher with anti-ficolin-3 or anti-C1q antibodies than with other auto-antibodies.
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Interestingly, the combination of anti-ficolin-3 and anti-C1q antibodies demonstrated higher
specificity than any other serological biomarker. These results suggest that anti-ficolin-3
antibodies could be useful for the diagnosis of active nephritis in SLE patients.
Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a prevalence of 4/
10,000 among Northern Europeans and a predisposition of women of childbearing age [1].
SLE is characterized by the presence of circulating autoantibodies directed against self-anti-
gens, such as dsDNA, nuclear antigens and several cytoplasmic components [2]. The accumu-
lation of the resulting immune complexes mediates a systemic inflammatory response that is
the primary cause of tissue damage. Recently, defects in apoptotic cells clearance leading to sec-
ondary cell necrosis and subsequent release of intracellular autoantigens has been proposed as
one of the mechanisms of induction of these autoantibodies [3] [4]. According to this proposal,
molecules of importance in the uptake of dying cells could have a role in host protection
against autoimmune diseases, including SLE [5] [6] [7] [8].
Apart from its well characterized anti-microbial role, the complement system has also a piv-
otal role in maintaining host integrity by eliminating apoptotic and damaged cells as well as by
clearing circulating immune complexes [9]. Indeed, deficiencies in early complement compo-
nents are often associated with increased susceptibility to both infections and autoimmune dis-
eases such as SLE, supporting a protective role for the complement system. Mice deficient for
C1q, the recognition protein of the classical complement pathway, are predisposed to SLE-like
diseases [10] and human studies report that hereditary homozygous deficiencies of C1q are
strongly associated with susceptibility to SLE, with a defect in apoptotic cells uptake by macro-
phages in SLE patients [11]. Recent reports suggest a role for mannan-binding lectin (MBL), a
recognition protein of the lectin complement pathway, in the pathogenesis of SLE [12]. Indeed,
gene polymorphisms leading to reduced levels of serumMBL were found associated with a pre-
disposition to SLE [13]. However, althoughMBL-null mice exhibit defective clearance of apo-
ptotic cells, they fail to develop symptoms of autoimmune diseases, suggesting the ability of
other molecules to compensate for MBL deficiency [14].
The potential role of the recently identified complement-activating lectin-like proteins fico-
lins (ficolin-1, -2 and -3, also referred as M-, L- and H-ficolins) has been suggested, since these
proteins appear to mediate immune effector functions similar to those of MBL and C1q [14]
[15]. Among these proteins, Ficolin-3 deserves special attention in the context of autoimmu-
nity since it was initially characterized as a serum antigen target (Hakata antigen) for an auto-
antibody present in a Japanese patient with SLE [16]. Ficolin-3 has poor lectin-like activity, as
shown by glycan array screening, but it binds to acetylated albumin with high affinity [17] [18].
It has been shown to specifically recognize few bacterial polysaccharides [19] [20]. Interest-
ingly, binding of ficolin-3 to apoptotic material has clearly been shown and has been postulated
to play a role in the clearance of apoptotic debris via phagocytosis [21] [22]. Recently, an asso-
ciation of high levels of ficolin-3 with specificmanifestations in SLE, but not with disease activ-
ity, was reported [23]. To date, only one study reported the presence of anti-ficolin-3
antibodies in SLE sera using a precipitation reaction for antibodies detection, and its correla-
tion with disease activity [24].
Our study aims to investigate the presence of anti-ficolin-3 antibodies in SLE patients and
to evaluate their potential as diagnostic and/or prognostic SLE biomarkers.
Anti-Ficolin-3 Autoantibodies in Lupus Nephritis
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Materials andMethods
Study
This study is a multicentric non-interventional retrospective study conducted in French Uni-
versity Hospitals (Grenoble University Hospital and Marseille University Hospital, France)
over a 3-year period (2012–2014).
Samples
All venous blood samples were obtained from patients referred for routine detection of auto-
antibodies and sera were conserved in a declared biobank DC 2012–1704 for Marseille and DC
2014–2268 for Grenoble, with respect of ethical directives.
Samples from SLE patients, satisfying the revised 1997 American College of Rheumatology
(ACR) classification criteria for SLE [25] (n = 165), were selected to be further analyzed in this
study. Samples from healthy blood donors (n = 48) obtained from “Etablissement Français du
Sang”, matched for sex and age, served as controls. This study has been approved by local
authorities (Institutional ReviewBoard) according to standards currently applied in France
(CommissionNationale de l’Informatique et des Libertés”, CNIL N°1841851vO). The study
has also been registered to clinicaltrial.gov (N° NCT02625831). The study was done in accor-
dance with the Declaration of Helsinki and GoodClinical Practice guidelines.
For SLE patients, clinical and biologicalmanifestations as well as treatments received and
disease activity evaluated using the Systemic Lupus ErythematosusDisease Activity Index
(SLEDAI) [26] at the time of sampling were recorded. The SLE patients were divided into two
groups for further analyses: a group with quiescent or “low disease activity” (n = 88) and a
group with active or “high disease activity” (n = 77), according to the physician in charge and
respectively with a SLEDAI score4 and>4. All patients with renal involvement had an active
lupus nephritis (LN) documented by kidney biopsy (classes I, II, III, IV or V of the ISN/RPS
classification) [27]. Samples were collected just before kidney biopsy. Active proliferation was
defined by the presence of at least one glomerulus showing cellular or fibro-cellular crescent or
endocapillary proliferation on kidney biopsy (classes III and IV).
Anti-ficolin-3antibodies assessment
Recombinant ficolin-3 was purified from the culture supernatant of a stably transfected
CHO cell line by affinity chromatography based on its binding capacity to acetylated BSA, as
previously described [28]. Detection of anti-ficolin-3 antibodies was adapted from an ELISA
previously described for measurement of anti-MBL antibodies [29]. Microtiter plates (96
wells) were coated overnight at 4°C with 2 μg/ml of recombinant ficolin-3 in 15 mM
Na2CO3, 35 mMNaHCO3 (pH 9.6). The plates were washed three times with Phosphate
Buffer Saline (PBS) containing 0.1% Tween-20 (w/v) (PBS-T) and blocked for 2 h at room
temperature (RT) with PBS-T containing 1% BSA (w/v). Serum samples were added to the
wells and incubated overnight at 4°C. After washing as above, horseradish peroxidase
(HRP)-conjugated goat polyclonal anti-human IgGs (The Binding Site, dilution 1/15 000)
were added for 1 h at RT. Subsequently, tetramethylbenzidine substrate was added to each
well, the reaction was stopped by addition of H2SO4 and optical densities (ODs) were mea-
sured at 450 nm. The threshold value of 70 AU was calculated using the 98th percentile on
the OD reading for the control group. A value was considered significantly elevated when the
concentration was above 70 AU (arbitrary units). The concentration was defined as (OD
sample/OD control) x 100 AU.
Anti-Ficolin-3 Autoantibodies in Lupus Nephritis
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Ficolin-3 assessment
To quantify ficolin-3 in healthy blood donors and SLE patients’ sera, an in-house ELISA was
adapted fromMichalski et al. [30]. Microtiter plates were coated with 2.5 μg/ml of mouse
monoclonal anti-human ficolin-3 (mAb 334, Hycult Biotechnologies) diluted in PBS (1:400)
overnight at 4°C. Plates were washed 3 times with PBS-T and blocked for 2 h with PBS-T-BSA
1% (w/v) at RT. After 3 washings with PBS-T, serum samples (1:50 dilution in PBS) or recom-
binant ficolin-3 were added to each well (100μl/well) at different concentrations to establish
the standard curve. After 3 h incubation at 37°C, the plates were washed 4 times with PBS-T,
and an in-house rabbit polyclonal anti-human ficolin-3 (1:2000 dilution in PBS-T) was added
and incubated 1 h at 37°C. After 4 washings with PBS-T, HRP-conjugated rabbit polyclonal
anti-ficolin-3 (1:5000 diluted in PBS-T) was added and incubated 1 h at 37°C. Detectionwas
achieved as described above.
Anti-dsDNAand anti-C1q antibodies assessment
Anti-double-stranded (ds)DNA antibodies were detected by ELISA (BIORAD) with normal
value defined as<50 U/ml. For anti-C1q antibodies,microtiter plates (96 wells) were coated
overnight at 4°C with 100 μl/well of purifiedC1q collagen stalks at 10 μg/ml in 20 mMH3BO3,
7.5 mMNaCl (pH 8.2) [31]. The plates were washed three times with PBS-T and blocked for 30
min at 37°C with PBS-T containing 2% BSA (w/v). Serum samples were added to the wells and
incubated 30 min at 37°C. After washings as above, HRP-conjugated goat polyclonal anti-human
IgG (The Binding Site, dilution 1:60,000) were added for 30 min at 37°C. Detectionwas achieved
as describedabove. The threshold value was calculated using the 98th percentile on the OD read-
ing for the control group. The concentration of IgG reactive to anti-C1q was expressed in arbi-
trary units (AU). The concentration was defined as (OD sample/OD cut-off)x 100 AU. A value
was considered significantly elevated when the concentration was above 100 AU.
Complement fractions assessment
Complement levels were measured by nephelometry (BNII, Siemens), according to manufac-
turer’s instructions, with the normal range for C4 being>100 mg/l and for C3>880 mg/l.
Statistics
Data analyses were carried out using Statview software version 5.0. Comparisons of continuous
variables between subgroups were done using Mann-Whitney non parametric U-test. Correla-
tions between continuous variables were assessed calculating Spearman’s rank correlation coef-
ficients. Comparisons of categorical variables, expressed as counts (%), were done using Chi²-
or Fisher’s exact-tests. P-values lower than 0.05 were considered statistically significant.
Results
Characteristicsof SLE patients
Details on the characteristics of the 165 SLE patients and matched healthy controls are pro-
vided in Table 1. The median age of the patients was 42 years (range 16–84 years), 88% were
women. At inclusion, the median SLEDAI score was 4 (range 0–24). 88 patients were classified
in the “low disease activity” group and 77 in the “high disease activity” group, as previously
defined (seeMethods). In this latter group, 36 (47%) patients had biopsy-proven active lupus
nephritis.
Anti-Ficolin-3 Autoantibodies in Lupus Nephritis
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Prevalence of anti-ficolin-3antibodies in SLE patients
The presence of anti-ficolin-3 antibodies was first investigated in sera obtained from one SLE
patient and one healthy blood donor. A dose-dependent binding of IgG to solid-phase ficolin-3
was demonstrated, while serum from a healthy blood donor did not show significant reactivity
(Fig 1A). Those sera were used as positive and negative standards for further experiments. As a
control, ELISA wells were coated with BSA and no detectable binding was observed for both
sera.
Subsequently, anti-ficolin-3 antibodies were tested in serum samples from the 165 SLE
patients and from 48 healthy controls. Titers of anti-ficolin-3 antibodies were significantly
higher in SLE patients than in healthy controls (median 45 vs 25 AU, p<0.0001, Mann-Whit-
ney U-test) (Fig 1B). Using a cutoff value of 70 AU (seeMethods) anti-ficolin-3 antibodies
were detected as positive in 56 (34%) of 165 SLE patients. No anti-ficolin-3 antibodies were
found in patients with rheumatoid arthritis (n = 14), Sjögren’s syndrome (n = 12), chronic
renal failure (n = 12) and IgA nephropathy such as Berger disease (n = 12) (S1 Fig).
Association between anti-ficolin-3antibodies levels and clinical and
biological SLE activity
In SLE patients, the titers of anti-ficolin-3 antibodies were significantly associated with the
titers of anti-dsDNA antibodies (r = 0.46, p<0.0001, Spearman test) (Fig 2A) as well as with
the titers of anti-C1q antibodies (r = 0.38, p<0.0001, Spearman test) (Fig 2B). The presence of
anti-ficolin-3 antibodies was not correlated to ficolin-3 serum levels (r = 0.14, p = 0.08, Spear-
man test) (Fig 2C). Furthermore, a statistical difference in serum ficolin-3 concentrations was
observedbetween SLE patients and healthy individuals (p = 0.015, Mann-Whitney U-test) (S2
Fig).
A significant association between anti-ficolin-3 antibodies titers and disease activity (SLE-
DAI) was observed (r = 0.38, p<0.0001, Spearman test) (Fig 2D). Similar results were obtained
using a clinical SLEDAI, which does not take anti-dsDNA antibodies and complement titers
into account. A significant association was also observedbetween SLEDAI score and titers of
anti-dsDNA antibodies (r = 0.62, p<0.0001, Spearman test) or titers of anti-C1q antibodies
(r = 0.38, p<0.0001, Spearman test). Of note, ficolin-3 levels were not associated with lupus
activity evaluated by SLEDAI score (r = 0.296, p = 0.083, Spearman test) (S3 Fig).
Table 1. Demographic and clinical variables for SLE patients.
Demographic variables Control (n = 48) SLE (n = 165)
Age, range, years 25–70 16–84
Age, mean (median) (S.D), years 41 (38) (13.3) 44 (42) (15.5)
Gender, female, n (%) 42 (88) 145 (88)
Clinical features, n (%) NA
Kidney 38 (23)
Joint 34 (21)
Haematological 10 (6)
Cutaneous 16 (10)
Cardiac 5 (3)
Pulmonary 2 (1)
Neurological 4 (2)
It should be noted that some patientsmay have lupus flare involving several organs. NA: not applicable.
doi:10.1371/journal.pone.0160879.t001
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Fig 1. Detection of anti-ficolin-3 antibodies in patientswith SLE.A) Binding of anti-ficolin-3 antibodies to
immobilized ficolin-3.Microtiter plates were coated with ficolin-3. Sera fromSLE patients and healthy controls
were added in serial dilutions. Results represent the mean +/- standard deviation. B) Anti-ficolin-3 antibodies
in serumsamples. Anti-ficolin-3antibodieswere measured in 48 samples from healthy controls and in 165
samples from patients with SLE. Horizontal lines in each group indicate themedian values. Statistical
analyses were performed by Mann-Whitney test. A, absorbance; AU, Arbitrary units.
doi:10.1371/journal.pone.0160879.g001
Anti-Ficolin-3 Autoantibodies in Lupus Nephritis
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Association between SLE-related clinical features and autoantibodies
positivity
Among various clinical manifestations presented by our patients (Table 2), the presence of
anti-ficolin-3 antibodies was significantly associated with lupus nephritis (p0.001, Chi2 test).
Similarly, the presence of anti-C1q antibodies was also significantly associated with lupus
nephritis (p0.001, Chi2 test). Anti-dsDNA antibodies and low complement C3 and/or C4
were less associated with kidney involvement (respectively p = 0.012 and p = 0.015, Chi2 test).
Anti-ficolin-3antibodies and active lupus nephritis
Anti-ficolin-3 antibodies were detected as positive in 38 (49%) of the 77 SLE patients character-
ized as having “high disease activity”. Titers of anti-ficolin-3 antibodies were significantly
higher in SLE patients with “high disease activity” than in those with “low disease activity”
(median 69 vs 35 AU, p<0.0001, Mann-Whitney U-test), (Fig 3A). Anti-ficolin-3 antibodies
were detected as positive in 25 (69%) of 36 SLE patients with active disease and lupus nephritis.
Characteristics of the patients are shown in Table 3. Interestingly, titers of anti-ficolin-3 anti-
bodies were significantly higher in this subset of SLE patients with active disease and lupus
Fig 2. Associationbetween anti-ficolin-3 antibodies titers, biological markers and disease activity in patientswith SLE. Association between anti-
ficolin-3 titers and anti-dsDNAantibodies (A), anti-C1q antibodies (B) and ficolin-3 concentrations (C) in SLE. D) Association between anti-ficolin-3 titers
and SLE Disease Activity Index (SLEDAI). Statistical analyses were performedby Spearman’s rank correlation test.
doi:10.1371/journal.pone.0160879.g002
Anti-Ficolin-3 Autoantibodies in Lupus Nephritis
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nephritis than in patients with active disease but without renal involvement (median 102 vs 54
AU, p = 0.0016, Mann-Whitney U-test) (Fig 3B).
Lupus nephritis and combined biomarkers
As anti-ficolin-3, anti-C1q, anti-dsDNA and low complement C3 and/or C4 were associated
with renal disease activity, we characterized the diagnostic performances of these biomarkers,
alone or in combination, in our cohort. Sensitivity and specificity of anti-ficolin-3 antibodies
for SLE renal involvement were respectively 70% and 68%. Predictive positive and negative val-
ues were respectively 66% and 72%.While anti-dsDNA antibodies alone indicated a better sen-
sitivity than the other biomarkers, interestingly the combination of anti-ficolin-3 and anti-C1q
antibodies showed the higher specificity for renal involvement (Table 4).
We then analyzed the possible link between the presence of anti-ficolin-3 antibodies and
immunohistological characteristics of the 36 kidney biopsies. Patients with active proliferative
lupus nephritis (i.e. Classes III and IV) had significantlymore positive anti-ficolin-3 and anti-
C1q antibodies than those with non-proliferative lupus nephritis (respectively p = 0.001 and
p = 0.006, Fisher’s exact test) (Table 5). Other biological data such as proteinuria, abnormal
creatinine, low complement and anti-DNA antibodies were not or little significantly different
between the two groups.
Discussion
Our study is to our knowledge the first one assessing the presence of antibodies targeting fico-
lin-3 and measuring their titers using an ELISAmethod in SLE patients. Indeed, only one pre-
vious study reported the presence of auto-antibodies against ficolin-3 in lupus sera, but authors
used a double immunodiffusion technique which was not quantitative [24]. In that study, only
4 among 110 SLE patients (3.6%) were found to have anti-ficolin-3 antibodies. Conversely, in
our cohort, 57/165 (34%) patients were found positive. This discrepancy likely relies on the
higher sensitivity of our ELISA over older techniques.
The present study is also the first to investigate association between anti-ficolin-3 antibodies
and clinical and serologic parameters of SLE using a large cohort of SLE patients. First, we
found that the anti-ficolin-3 autoantibodies levels were significantly higher in SLE patients as
compared to healthy subjects. Interestingly, these antibodies were found negative in other
Table 2. AssociationsbetweenSLE-relatedclinical features of 77 patientswith active SLE and titers of anti-ficolin-3, anti-C1qand anti-dsDNA
antibodies.
SLE damages Number of patientswith flare Anti-ficolin-3 Anti-C1q Anti-dsDNA Low complement
Chi-2 p Chi-2 p Chi-2 p Chi-2 p
Kidney 36 10.92 *** 0.001 12.72 *** 0.001 6.36 * 0.012 5.87 * 0.015
Joint 33 3.90 * 0.048 10.90 *** 0.001 5.53 * 0.019 10.84 *** 0.001
Haematological 8 0.002 0.970 1.62 0.203 0.10 0.756 2.60 0.107
Cutaneous 16 7.57 ** 0.006 1.73 0.188 6.47 * 0.011 0.03 0.861
Cardiac 5 0.19 0.665 0.14 0.710 0.002 0.965 0.14 0.709
Pulmonary 2 2.11 0.147 4.27 * 0.039 0.54 0.463 0.003 0.955
Neurological 4 0.001 0.979 0.11 0.743 2.19 0.139 1.23 0.268
It should be noted that some patientsmay have lupus flare involving several organs.
*P0.05
**P0.01
***P0.001 (Chi2-test).
doi:10.1371/journal.pone.0160879.t002
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Fig 3. Serumanti-ficolin-3 antibodies titers in SLE patients with active disease (flare) or in disease
remission.A) Anti-ficolin-3 titers in SLE patients with active disease (SLEDAI >4) (n = 77) or in disease
remission (SLEDAI4) (n = 88). B) Anti-ficolin-3 titers in SLE patients with active disease with renal
involvement (n = 36) or without renal involvement (n = 41). Horizontal lines in each group indicate the median
values. Statistical analyses were performed by Mann-Whitney test.
doi:10.1371/journal.pone.0160879.g003
Anti-Ficolin-3 Autoantibodies in Lupus Nephritis
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autoimmune diseases such as rheumatoid arthritis and Sjögren’s syndrome. Then we assessed
the presence of anti-ficolin-3 antibodies in sera of SLE patients during inactive and active
phases of the disease. The levels of anti-ficolin-3 were significantly higher in patients with
active than quiescent disease and we observed a statistical correlation of antibodies levels and
the global activity of the disease evaluated by the SLEDAI score.
These findings are of importance. Indeed, while many tests exist for the detection of autoan-
tibodies in the sera of patients with SLE, such as anti-dsDNA and anti-C1q [32], only few of
them are used in clinical practice.Most of the studies indicated that anti-dsDNA antibodies
could be usefulmarkers of the overall activity of SLE [33]. Some considered the elevated levels
of anti-dsDNA as indicative of active forms of SLE [34]. In accordance with those observations,
titers of anti-dsDNA were correlated with lupus activity in our SLE cohort. However, some
studies suggested that anti-dsDNA antibodies have to be used with caution to evaluate the SLE
activity [35] [36]. Because the associations between antibody profile and clinical symptoms are
unclear, it is crucial to find new relevant diagnostic and/or prognostic biomarkers.
Similarities in structure and function exist between collagen-like defense molecules such as
MBL, C1q and ficolin-3. Anti-MBL antibodies were found in SLE patients’ sera but no signifi-
cant relationship was observedwith clinical characteristics of SLE [29] [37]. Several studies
reported that anti-C1q levels did not correlate with SLEDAI score in SLE patients [36] [38].
However, in our study, we found an association between titers of anti-C1q and SLE disease
activity, in accordance with the study of Moura et al. [39]. The occurrence of anti-C1q antibod-
ies in patients with active lupus nephritis remains controversial but the absence of anti-C1q
antibodies seems to exclude active renal disease [40] [41].
Lupus nephritis, a severe manifestation of SLE, affects up to 30 to 50% patients in the course
of the disease. Interestingly, in our cohort we observed a very high prevalence (70%) of anti-
ficolin-3 antibodies in the subset of SLE patients with lupus nephritis. Regarding clinical associ-
ations, anti-ficolin-3 antibodies positivity was significantly related to renal involvement. There
Table 3. Characteristics of SLE patientswith lupus nephritis.
Demographic data Age, mean +/- SD 36 +/- 14.6
Male/Female, n (%) 12 (33) / 24 (67)
White/African/Asian, n (%) 30 (83)/5 (14)/1 (3)
Renal abnormalities Urinarycasts (heme-granular or RBC casts) 24 (69)
n (%) High blood pressure 6 (17)
Proteinuria 34 (94)
Abnormal creatinine 13 (36)
ISN/RPS 2003 class I 2 (6)
n (%) II 1 (3)
III 4 (11)
IV 23 (64)
V 6 (17)
Therapy Corticoids 21 (58)
n (%) Azathioprine 3 (8)
Plaquenil 13 (36)
Methotrexate 1 (3)
Rituximab 2 (6)
Mycophenolate mofetil 3 (8)
RBC, red blood cells
doi:10.1371/journal.pone.0160879.t003
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was no significant association between the positivity of anti-ficolin-3 antibodies and other clin-
ical characteristics of SLE such as joint, hematological, neurological, cardiac or pulmonary
damages. This is in accordance with our results showing significantly higher anti-ficolin-3
titers in patients with active nephritis compared to those in patients with active disease but
without renal involvement. Moreover, the possibility that renal dysfunctionmight lead to
higher level of antibody has been eliminated since anti-ficolin-3 antibodies were found negative
in dialyzed patients with chronic renal failure. Importantly, we found that anti-ficolin-3 anti-
bodies were more closely associated with active lupus nephritis than any other auto-antibodies.
The development of nephritis is a major determinant of diseasemorbidity and mortality. Thus,
the identification of non-invasive biomarkers in lupus nephritis is a priority. We observed that
the combination of anti-ficolin-3 and anti-C1q antibodies outperformed anti-C1q, anti-
dsDNA or low complement alone, demonstrating a higher specificity than either serological
biomarker. Until now, anti-C1q in combination with anti-dsDNA and low complement was
reported as the strongest serological association with renal involvement. Orbai et al. and Yang
et al. showed that the combination of anti-C1q and anti-dsDNA was associated with higher
renal disease activity [42] [43]. Even if nephritis assessment based on standard parameters
such as proteinuria and creatinine remains essential, the combination of anti-ficolin-3 and
anti-C1q antibodies could open new perspectives in evaluation of lupus nephritis.
Although a causal relationship between the presence of anti-ficolin-3 antibodies and lupus
nephritis remains to be determined, the possible role of anti-ficolin-3 antibodies in the patho-
genesis of lupus is a key issue. On one hand, anti-ficolin-3 antibodiesmay contribute to the for-
mation of circulating immune complexes that are deposited in the kidney or to the local
formation of immune complexes on the glomerular basement membrane. On the other hand,
anti-ficolin-3 antibodies from SLE patients could specifically target ficolin-3 bound to
Table 4. Performances of SLE biomarkers.
Biomarkers Renal flare No renal flare Sensitivity (%) Specificity (%) NPV (%) PPV (%)
Anti-ficolin-3 Abs 25/36 (70%) 13/41 (32%) 70 68 72 66
Anti-dsDNAAbs 33/36 (92%) 28/41 (68%) 92 32 81 54
Anti-C1qAbs 19/36 (53%) 6/41 (15%) 53 85 67 76
Low complement 24/36 (67%) 16/41 (39%) 66 61 68 60
Anti-ficolin-3 and anti-C1qAbs 18/36 (50%) 3/41 (7%) 50 93 68 86
Anti-ficolin-3 and anti-C1q Abs and low complement 15/36 (42%) 3/41 (7%) 42 93 64 83
Abs, antibodies; NPV, negative predictive value; PPV, positive predictive value.
doi:10.1371/journal.pone.0160879.t004
Table 5. Biological characteristics of patientswith active and inactive lupus nephritis.
LN with non active proliferation n = 9 (%) LNwith active proliferation n = 27 (%) P
Proteinuria 9 (100) 25 (93) 1.00
Abnormal creatinine 1 (11) 12 (44) 0.11
Low complement 3 (33) 21 (78) 0.04 *
Anti-dsDNAAbs 7 (78) 26 (96) 0.15
Anti-C1q Abs 1 (11) 18 (67) 0.006 **
Anti-ficolin-3 Abs 2 (22) 23 (85) 0.001 ***
*P0.05
**P0.01
***P0.001 (Fisher’s exact-test)
doi:10.1371/journal.pone.0160879.t005
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apoptotic cells, thereby altering the clearance of dead cells, which is an important hypothesis of
the pathogenesis of SLE. This role of anti-ficolin-3 antibodies is plausible, because ficolin-3
seems not to be affected in SLE. Indeed, we found increased serum levels of ficolin-3 in patients
with SLE and no association of ficolin-3 levels and lupus activity, as shown by Andersen et al.
and Hein et al. [44] [23]. Therefore, the role of anti-ficolin-3 antibodies in the SLE pathogene-
sis remains to be investigated and an interesting point resides in identifying the auto-antibodies
specificities against ficolin-3. Indeed, anti-ficolin-3 antibodies could recognize either the colla-
gen-like or the fibrinogen-like domains of ficolin-3 with different outcomes. A significant par-
ticipation of complement activation was reported in the pathogenesis of lupus nephritis. The
alternative and lectin pathways were involved in the progression of glomerular injury of
patients with lupus nephritis [45] and in situ deposition of complement components in renal
biopsy specimens has been shown [46]. Ficolin-3, which is a strong activator of the lectin path-
way, could also contribute to renal pathogenesis. Moreover, Pang et al. [47] showed that in the
presence of anti-C1q antibodies, immune complexes would not be removed from the circula-
tion and might prone to deposit in some organs, such as kidneys, and induce inflammatory
injury. The potential role of anti-ficolin-3 antibodies was not discussed in the literature and it
would be of interest to study the association between anti-ficolin-3 antibodies and specific
pathological lesions on kidney biopsies. In this regard, a link between the presence of anti-fico-
lin-3 antibodies and the immunohistological characteristics of the kidney biopsies was
observed.However further investigations would be necessary to confirm these findings in a
larger cohort of patients with lupus nephritis.
In conclusion, this is the first report on the significant presence of anti-ficolin-3 antibodies
in the serumof SLE patients. From a clinical point of view, these data support the usefulness of
anti-ficolin-3 as an additional serological biomarker for the diagnosis of active lupus with renal
manifestation, but additional longitudinal studies are needed to validate the diagnostic and/or
prognostic role of this new SLE parameter.
Supporting Information
S1 Fig. Detection of anti-ficolin-3 antibodies in patients with Sjögren’s Syndrome and
RheumatoidArthritis.Microtiter plates were coated with ficolin-3. Sera from healthy controls
(n = 48), Sjögren’s Syndrome (SS) (n = 12), Rheumatoid Arthritis (RA) (n = 14), chronic renal
failure (n = 12), IgA nephropathy such as Berger disease (n = 12) and SLE patients were added
in serial dilutions. Horizontal lines in each group indicate the median values. AU, arbitrary
units.
(TIF)
S2 Fig. Ficolin-3 levels in serum samples. Ficolin-3 was measured in 48 samples from healthy
controls and in 165 samples from patients with SLE. Horizontal lines in each group indicate
the median values. Statistical analyses were performed by Mann-Whitney test.
(TIF)
S3 Fig. Association between ficolin-3 levels and DiseaseActivity Index (SLEDAI) in
patients with SLE. Statistical analyses were performed by Spearman’s rank correlation test.
(TIF)
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